Company (Location) Product Description Indication Status Date AUTOIMMUNE Anthera Pharmaceuticals Inc. (Hayward, Calif.) Blisibimod A peptibody antagonist of BAFF Lupus Started a Phase III trial 3/29/13 Biogen Idec Inc. (Weston, Mass.) Plegridy Peginterferon beta-1a Relapsing-remitting multiple sclerosis Two-year Phase III data showed it significantly reduced MS disease activity, including relapses, disability progression and brain lesions, compared to placebo at one year 3/21/13 Celgene Corp
Proceeds from the IPO would be used to fund clinical trials, R&D for additional AAT indications, expanding distribution capabilities to additional territories, expanding its manufacturing infrastructure and for general corporate purposes
By Jennifer Boggs | BioWorld Today | Monday, April 15, 2013
And at the opening press conference, where scientists announced the results of several clinical trials of immunotherapies, discussant Louis Weiner, of Washington University in St. Louis, went so far as to suggest that immunotherapy should be considered a fourth branch of cancer therapy, along with surgery, radiation and drug treatment...And so, Topalian and her team are planning a clinical trial that will explicitly test sequential treatment with epigenetic-targeting drugs and PD-1 blockade
By Anette Breindl | BioWorld Insight | Monday, April 15, 2013
Mills noted that the company has gained "experience with not only the drug for its effects, but also in manufacturing multiple lots for our clinical trials," so Acadia is "very comfortable with the chemical characteristics of the drug
By Randy Osborne | BioWorld Today | Friday, April 12, 2013
And at a standing-room-only session that explored how mice can be used to improve clinical trials rather than basic science, Genentech's Leisa Johnson enumerated the advantages of GEMMs...Anyone who wants to test each possible combination in clinical trials has "a serious problem – you will run out of patients to accrue
By Anette Breindl | BioWorld Today | Thursday, April 11, 2013
Alongside the Phase II evidence of safety and efficacy in glioblastoma, Activartis has evidence from academic clinical trials demonstrating the technology is applicable to other tumor types
Alongside the Phase II evidence of safety and efficacy in glioblastoma, Activartis has evidence from academic clinical trials demonstrating the technology is applicable to other tumor types
By Nuala Moran | BioWorld Today | Wednesday, April 10, 2013
Alongside the Phase II evidence of safety and efficacy in glioblastoma, Activartis has evidence from academic clinical trials demonstrating the technology is applicable to other tumor types
By Nuala Moran | BioWorld International | Wednesday, April 10, 2013
For now, the bulk of clinical trials targeting epigenetic mechanisms is still at an early stage...Those clinical trials, he said, will be "the ultimate test of the whole hypothesis
For now, the bulk of clinical trials targeting epigenetic mechanisms is still at an early stage...Those clinical trials, he said, will be "the ultimate test of the whole hypothesis
By Anette Breindl | BioWorld Today | Tuesday, April 9, 2013
RN-307 was discovered and originally developed by Rinat Neuroscience Corp., a South San Francisco protein therapeutics company that was acquired by Pfizer in 2006. (See BioWorld Today, April 10, 2006.) In a Series C financing Versartis Inc., of Redwood City, Calif., raised $25 million to support clinical trials of its product candidate VRS-317 for growth hormone deficiency in children. (See BioWorld Today, Jan. 16, 2013.) The drug is a once-monthly form of recombinant human growth hormone (HGH
By Peter Winter | BioWorld Insight | Monday, April 8, 2013
The complex asset contribution agreement involves multiple transfers of common stock and warrants, along with patents, regulatory filings and investigational new drug (IND) applications filed with the FDA for Geron's Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury – the first FDA-approved ESC clinical trial. (See BioWorld Today, Jan. 26, 2009, and Jan. 27, 2009.) The S-1 represented the first step to
By Marie Powers | BioWorld Today | Friday, April 5, 2013
Net proceeds will be used to cover costs related to the new drug application for CompleoTRT, making a milestone payment for CompleoTRT, manufacturing scale-up for CompleoTRT and Tefina clinical trials
Jose Baselga, physician-in-chief at Memorial Sloan-Kettering Cancer Center and the chairman of the program committee for the 2013 annual meeting, said in a recorded greeting that the data being presented at the conference span the trajectory from basic biology to clinical trial results
By Anette Breindl | BioWorld Today | Friday, April 5, 2013
Haynes and his colleagues said they hope that by understanding the road traveled by the broadly neutralizing antibody their subject produced, they will be able to develop a series of antigens that can be used to induce broadly neutralizing antibodies via a series of vaccinations – though Haynes' response when asked when such a vaccine might enter clinical trials was succinct: "I don't know
By Anette Breindl | BioWorld Today | Thursday, April 4, 2013
Company (Location) Product Description Indication Status Date AUTOIMMUNE Anthera Pharmaceuticals Inc. (Hayward, Calif.) Blisibimod A peptibody antagonist of BAFF Lupus Started a Phase III trial 3/29/13 Biogen Idec Inc. (Weston, Mass.) Plegridy Peginterferon beta-1a Relapsing-remitting multiple sclerosis Two-year Phase III data showed it significantly reduced MS disease activity, including relapses, disability progression and brain lesions, compared to placebo at one year 3/21/13 Celgene Corp